Conditions: Atherosclerosis Ischemia Myocardial Infarction Cerebrovascular Accident Peripheral Arterial Disease
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 26449
Healthy volunteers: no

Brief summary:
The study is designed to determine whether vorapaxar, when added to the existing standard of care (SOC) for preventing heart attack and stroke (eg, aspirin, clopidogrel) in participants with a known history of atherosclerosis, will yield additional benefit over the existing standard of care without vorapaxar in preventing heart attack and stroke.

The study is also designed to assess risk of bleeding with vorapaxar added to the standard of care versus the standard of care alone.

Detailed description:

Arms:
arm 1: 1 placebo tablet, orally, daily for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care. arm 2: one 2.5 mg tablet daily, orally, for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care.

Interventions: intervention 1: Vorapaxar intervention 2: Placebo
Intervention descriptions: intervention 1: 2.5-mg tablet daily for at least 1 year intervention 2: matching tablet daily for at least 1 year

Protocol document: